Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 2Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Terminated 4Unknown 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 72Breast Neoplasms 63Neoplasms 59Leukemia, Myeloid, Acute 59Multiple Myeloma 53Colorectal Neoplasms 48Lymphoma 46Recurrence 45Carcinoma, Hepatocellular 45Stomach Neoplasms 43Pancreatic Neoplasms 40Neoplasm Metastasis 39Prostatic Neoplasms 34Melanoma 34Leukemia 30Lymphoma, Non-Hodgkin 27Lymphoma, B-Cell 27Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 24Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 21Esophageal Neoplasms 21Carcinoma, Renal Cell 20Myelodysplastic Syndromes 19Leukemia, Lymphocytic, Chronic, B-Cell 19Hematologic Neoplasms 19Colonic Neoplasms 19Head and Neck Neoplasms 18Lymphoma, Mantle-Cell 17

Interventions

Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × HER2-positive Breast Cancer × Clear all
NCT04170595 2021-03-03

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

Genor Biopharma Co., Ltd.

Phase 1/2 Unknown
132 enrolled
Breast

HER2-positive Breast Cancer

NCT03881878 2019-03-21

TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Samsung Medical Center

Phase 1/2 Unknown
67 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡